New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
06:24 EDTAZNAstraZeneca: Headwinds to remain challenging, FT reports
After reporting a 6% y/y decline in revenue to $6.84B, AstraZeneca CEO Pascal Soriot says he believes headwinds will remain challenges as the company faces more patent losses on Nexium and Crestor drugs over the next two years, the Financial Times reports. At the same time, Soriot believes the company can return to growth quicker than expected and believes 2017 revenues will be "broadly in line" with 2013. Reference Link
News For AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:51 EDTAZNRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 24, 2015
05:13 EDTAZNAstraZeneca to collaborate with Peregrine on cancer immunotherapy clinical trial
Subscribe for More Information
August 23, 2015
12:35 EDTAZNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
11:33 EDTAZNLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:23 EDTAZNAdvaxis, MedImmune begin enrollment in axalimogene filolisbac Phase I/II study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use